Northwest Biotherapeutics (NWBO) is suing Citadel Securities, Susquehanna International, and other names on the Street for manipulating its share price via illegal trades, according to the Wall Street Journal.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The biotechnology company has accused market-making firms of ‘spoofing’ the order book (a flurry of orders that are canceled immediately) which led to a decline in its share price.
NWBO shares have gained nearly 10.6% year-to-date.
Read full Disclosure